C opy number variations (CNVs) are thought to be an important mechanism of genomic diversity and evolutionary changes in humans. 1, 2 Often, CNVs are seen in healthy control individuals, and determination of the pathogenicity of newly identified CNVs can be challenging. Since 2004, genome-wide identification of CNVs has become efficient through array comparative genomic hybridization, allowing the detection of causative submicroscopic CNVs that were not previously identified by karyotype, 1, 3 especially in neuropsychiatric disorders. 4 The importance of rare CNVs has been well recognized in patients with epilepsy with partial and generalized seizures, 5, 6 epileptic encephalopathies, 7 genetic generalized epilepsy with intellectual disability (ID), 8, 9 atypical Rolandic epilepsy, 10 feverassociated syndromes, 11 and absence epilepsy. 12 Rare CNVs have also been identified in individuals with developmental disabilities and/or congenital anomalies. 13, 14 Of note, these comorbidities are seen in a high proportion of adult patients who did not outgrow their childhood-onset epilepsies. 15 In an adult epilepsy clinic, it can be difficult to diagnose specific childhood-onset epilepsy syndromes for several reasons. The clinical features might have evolved since childhood. Key diagnostic features, such as characteristic electroencephalograms (EEGs), or certain seizure types may no longer be present; even if phenotyping were performed during childhood, without those previous notes, the current features may no longer be enough for a clinical diagnosis. In addition, parents often have difficulties remembering the characteristics of certain seizures that have long been replaced by other seizure types. Finally, for some patients, despite phenotyping, the clinical manifestations are not diagnostic of any specific epileptic syndrome. Therefore, genetic testing in adults, interpreted in light of clinical features, may help clarify the etiologic diagnosis. 16, 17 We sought to determine the prevalence of pathogenic and likely pathogenic CNVs in adults with pediatric-onset epilepsy and ID of unknown origin. We also aimed to identify novel genes within these CNVs that may be related to seizures and could then be studied further and compared with similar cases.
Methods
Patients were recruited from the Toronto Western Hospital epilepsy outpatient clinic from January 1, 2012, through December 31, 2014. Inclusion criteria for this cross-sectional study were (1) onset of seizures between birth and adolescence and ongoing seizure activity throughout adulthood, (2) neither obvious causal structural abnormalities in their neuroimaging studies nor evident metabolic conditions that could explain their symptoms, and (3) ID of any degree, diagnosed through a formal neuropsychological evaluation and classified according to the
International Statistical Classification of Diseases and Related Health Problems, Tenth Revision
18 (when IQ test results were available) or DSM-5 19 (when patients could not be tested). The exclusion criteria were (1) patients presenting with a classic phenotype of chromosomal abnormalities (eg, Down syndrome) and (2) DNA of all patients was screened for CNVs using clinical genome-wide microarray platforms; labeling and hybridization were performed following standard protocols using platform 4 × 180K Oligonucleotide Array (Agilent Technologies) and CytoSure interpret (Oxford Gene Technologies) analysis software. Some samples were studied with CytoScan HD SNP Array (Affymetrix) genomic platform and ChAS (Affymetrix) analysis software.
Patients who harbored a CNV of interest were offered segregation testing. Available relatives were tested with fluorescence in situ hybridization (FISH) analysis with probes obtained from The Centre for Applied Genomics or with microarray testing using the same technology that was used to identify the CNV in their relatives. For the latter cases, only the region of interest was subject to analysis.
Pathogenicity of CNVs was predicted based on their size and gene content according to the American College of Medical Genetics guidelines for interpretation of CNV results. 20 Whenever known epilepsy genes were within the deleted or duplicated interval and there was a correlation with the patient's phenotype, the CNV was considered to be pathogenic.
For each relevant Online Mendelian Inheritance in Man (OMIM) gene that could play a role in the patient's phenotype, we applied the Residual Variation Intolerance Score (RVIS) and the percentile of most intolerant genes (MIG) to guide the interpretation of potential clinical significance. 21 The RVIS is based on allele frequency as represented in whole-exome sequence data from the National Heart, Lung, and Blood Institute Exome Sequencing Project 6500 data set. A gene with a positive score has more common functional variation, and a gene with a negative score has less variation and is referred to as intolerant. The more intolerant a gene is, the more likely it is associated with disease if mutated or at abnormal levels.
[10.8] years; 69 male and 74 female). There were 23 probands (16.1% of the total sample investigated) and 4 affected relatives (2.8%) with 1 or more pathogenic or likely pathogenic CNV ( Table 1) . The investigated patients' age ranged from 17 to 41 years (median, 22 years), and 16 were female. Among the 27 individuals with pathogenic and likely pathogenic CNVs, deletions were found in 15 patients and duplications in 10. These CNVs varied from 0.08 to 18.9 Mb (median, 4.84 Mb). Five probands had more than 1 CNV detected, including 2 patients with 2 pathogenic CNVs (patients 4 and 12; both had unbalanced translocations confirmed by FISH or G-banding), and 3 patients with a second CNV deemed to be a variant of unknown significance (patients 3, 18, and 21).
Parental testing revealed de novo CNVs in 11 of 23 probands (47.8%) and CNVs inherited from parents in 4 (17.4%), the latter representing unbalanced segregation of parental balanced rearrangements in 3 probands (patients 3, 4, and 6) and maternal X-linked inheritance in a male proband (patient 26). One mother (patient 6) presented with mild dysmorphic features similar to her offspring and borderline intellectual functioning.
Eight adult patients (34.8%) had only 1 or none of the parents available for testing. However, the CNVs in 7 of them (patients 12, 15, 16, 17, 18, 19, and 20) were pathogenic according to the American College of Medical Genetics guidelines. 20 The remaining patient (patient 21) had 1 likely pathogenic CNV and 1 large (>500 kb) variant of unknown significance. ABAT duplication (patient 21; 16p13.2 duplication) was identified in a 23-year-old man with developmental delay and a history of multiple seizure types since the age of 6 months. He died shortly after genetic testing was completed. Over time, his seizure phenotype evolved and became consistent with Lennox-Gastaut syndrome (LGS) with tonic, atonic, and atypical absence seizures and corroborant EEGs. He required partial callosotomy at the age of 4 years, ketogenic diet from the ages of 8 to 9 years, vagus nerve stimulator insertion when he was 10 years of age, and completion of callosotomy at 11 years of age. At the time of testing, he was nonverbal and incontinent and presented with a wide-based gait and bilateral hand dystonic posture. He had no dysmorphic features. The case was reviewed in the context of the CNV finding, and thus, cerebrospinal fluid γ-aminobutyric acid (GABA) testing could have provided support for GABA-transaminase overexpression as a consequence of his ABAT duplication. However, this analysis was not performed because his family decided to not pursue an invasive test.
COL4A1 deletion and CACNA1C duplication (patient 12; 13q34 deletion and 12p13.33-13.2 duplication) were seen in a 24-year-old woman with severe ID and dysmorphisms characterized by a prominent forehead, low hair implantation, and bilateral auricular appendix. She was born in Ethiopia to nonconsanguineous parents. There was no family history of seizures or ID. Seizure phenotype was characterized by bilateral convulsive seizures starting when the patient was 17 years of age; despite her severe ID, her EEG showed a normal background and spike and slow wave discharges over the left frontal and central regions. Seizures were controlled with levetiracetam and topiramate.
SMARCA2 deletion (patients 4 and 5; 9p24.3-p23 deletion and 6p25.3-p25.1 duplication) was present in a pair of siblings who developed focal-onset seizures in adolescence (15 and 17 years of age); their seizures have been controlled with monotherapy with levetiracetam. In addition to ID and autistic features, mood oscillation and intermittent aggression outbursts not aggravated (or ameliorated) by the antiepileptic therapy have been their main problems. The female sibling was born with cleft palate, and the male has developed sensorineural deafness over time.
Discussion
This study of adults with epilepsy and ID revealed that a high proportion of patients had clinically relevant CNVs. Twentythree probands (16.1%) had pathogenic or likely pathogenic CNVs, including 8 nonrecurrent rare CNVs. These CNVs encompassed genes that could explain the epilepsy and should be further studied. Of importance, this study underscores the 
CNVs in Adults With Epilepsy
The role of CNV has been well studied in children with seizures. 6, 7, 9 The largest study, 6 which analyzed 805 pediatric patients with epilepsy, reported a CNV as an explanation for the patient's phenotype in 5% of patients. In addition, in a systematic assessment 7 of epileptic encephalopathies, rare
CNVs were found in 7.9% of 315 patients. In 4.1%, the CNVs were pathogenic. 7 Only 1 study 49 has examined the presence of CNVs in adults with epilepsy and ID, and rare CNVs were present in 9.3% of 279 patients; however, only 29% of the patients studied had ID, and patients with severe ID, major neuropsychiatric issues, and epileptic encephalopathy were not included. In our cohort, all patients had some degree of ID, 47.8% of probands had autistic features, and 30.4% presented with other neuropsychiatric symptoms.
The current study indicates a higher prevalence of CNVs (16.1%) most likely because of our broader inclusion criteria, including patients with pharmacosensitive and pharmacoresistant seizure disorders associated with ID of variable severity. Another explanation for higher yield in our sample compared with the pediatric cohorts could be that studies in children may include patients in whom the phenotype was not entirely developed (eg, ID is not yet apparent or later onset of seizures). Although one could argue that the CNVs found in our study might be the cause of ID and not seizures, all CNVs (except 8p23.3p23.1 duplication and 10q11.22-q1.23 duplication) contain at least 1 gene in which heterozygous mutations have already been associated with epilepsy or that has a mechanism of action that could explain the occurrence of seizures (Table 1 and Table 2 ).
Of interest, for 69.5% of our cohort, the CNVs or genes present in those CNVs identified had been previously associated with well-known conditions, such as Angelman syndrome and 22q11.2 deletion syndrome. Although these genetic syndromes could have been diagnosed in childhood, (1) genetic tests were not available and/or easily performed when some of these adults were children, and karyotype was not capable of detecting the smaller CNVs currently detected by microarray; (2) mild or atypical phenotypes associated with classic genetic syndromes are sometimes difficult to recognize 50, 51 ; and (3) some of these conditions are relatively newly described compared with the median age of our cohort (eg, protocad- 
New Genetic Findings
The function of most genes identified in the 8 rare nonrecurrent CNVs in the present cohort was previously known, but the effect of hemizygous deletions or duplications was not always clear. As indicated in Table 2 , selected genes are expressed in the brain and, overall, present a lower threshold to variation according to their RVISs. Five notable candidate genes were found: ABAT in a patient with LGS; KIAA2022 in a patient with JS; and COL4A1, CACNA1C, and SMARCA2 in 2 patients with seizures and ID not characteristic of any known epileptic syndrome.
Four γ-aminobutyrate aminotransferase gene (ABAT) recessive mutations have been described; however, no duplication of this gene has been previously identified to our knowledge. Homozygous or compound heterozygous mutations lead to GABA-transaminase deficiency, causing a hyperGABAergic state. Such a hyper-GABAergic state underlies severe neurologic conditions characterized by psychomotor retardation and refractory seizures. [44] [45] [46] [47] [48] The EEGs in some of these patients have demonstrated hypsarrhythmia, 46 a condition that may evolve into LGS (which patient 21 with ABAT duplication also developed). It is not clear whether the patient's duplication led to higher amounts of GABAtransaminase and therefore a hypo-GABAergic state. Of interest, hypo-GABAergic states can also lead to epilepsy with a wide spectrum of seizure severity but not yet including LGS. 52 The definitive diagnosis usually requires measuring levels of GABA in the cerebrospinal fluid or its activity in liver or lymphocytes, but GABA-transaminase activity analysis was not available. However, one could hypothesize that ABAT duplication could be causative of the LGS phenotype in patient 21.
Patient 27 is a female with JS and an Xq13.3 de novo deletion overlapping the KIAA2022 gene. Male patients with KIAA2022 mutations have been described as having mild to severe ID and several types of seizures, including bilateral convulsive seizures, epileptic spasms, and LGS. 53, 54 Female patients with heterozygous KIAA2022 mutations may present with a milder phenotype compared with males, likely because of random X chromosome inactivation. A female patient with 100% inactivation of the normal X chromosome had a severe phenotype similar to that of males. 55 de Lange and colleagues 56 recently described 14 female patients with heterozygous de novo mutations of the KIAA2022 gene. Thirteen mutations resulted in a frameshift or premature stop codon that could elicit nonsense-mediated decay, predicting a complete loss of the protein function. Most of these female patients presented with intractable epilepsy with predominant myoclonic seizures and/or absences, with onset in infancy or early childhood, behavioral problems, and mild to severe ID. 56 Likewise, the phenotype in patient 27 is fairly similar to that in previously described patients except that eye closure-induced absence seizures (typical of JS) were not previously described. Thus, it appears that the deletion that contained the KIAA2022 gene identified in patient 27 may be associated with JS. With respect to the other genes less tolerant to variation found in our cohort, COL4A1, CACNA1C, and SMARCA2 had the most negative scores. COL4A1 was found in the 13q34 deletion and CACNA1C in the 12p13.33-13.2 duplication, both in patient 12. This patient did not have clinical and neuroimaging abnormalities previously associated with COL4A1 mutations, 57, 58 such as porencephaly, which is usually accompanied by perinatal intraventricular hemorrhage; brain small vessel disease with or without ocular anomalies; or hereditary angiopathy with nephropathy, aneurysms, and muscle cramps. Of importance, this patient also presented with CACNA1C duplication. Heterozygous mutation in the CACNA1C gene causes Timothy syndrome, characterized by autosomal dominant inheritance, long QT syndrome with syndactyly, dysmorphic features, and neuropsychiatric involvement. This L-type calcium channel gene has not been associated with an epilepsy syndrome, but a patient who harbored 2 variants of unknown significance (12p13.33 duplication and 15q11.2 deletion) that overlapped the CACNA1C gene has been described. 42 The seizure phenotype was described as unspecified seizure disorder, with the EEG showing focal epileptiform activity and magnetic resonance imaging showing gray matter heterotopia. 42 At present, it is not possible to determine the effects of CACNA1C duplication in our patient, even though some of her craniofacial and neuropsychiatric findings are similar to Timothy syndrome despite absence of cardiac involvement. Finally, heterozygous mutations in the SMARCA2 gene cause Nicolaides-Baraitser syndrome, characterized by severe ID, short stature, microcephaly, sparse hair, brachydactyly, prominent interphalangeal joints, behavioral problems, and seizures. 38 Seizures have been reported in two-thirds of patients; however, the seizure phenotypes of such patients have not been detailed except by a single case report of a patient with myoclonic-astatic epilepsy. 59 In that report, Tang and colleagues 59 described an electrographic correlation of negative axial myoclonus, normal magnetic resonance imaging results, and good response to sodium valproate therapy in a patient with SMARCA2 missense mutation (c.3721C>G; p.Gln1241Glu). The patients in our study (patients 4 and 5) who had deletions, including SMARCA2, had some nonspecific features of Nicolaides-Baraitser syndrome, such as ID and behavioral problems. However, their seizures began in adolescence and had a focal onset. They never developed myoclonicastatic seizures and did not have the typical dysmorphic features described in Nicolaides-Baraitser syndrome.
Diagnosis in Adults
Identification of the origin of epilepsy and ID in adult patients finally ends their prolonged diagnostic process and the associated emotional 60 and financial costs. In addition, diagnosis can help in making treatment decisions; for instance, adults with 22q11.2 deletion (patients 23 and 24) can develop Parkinson disease, and 50% of these patients have psychiatric problems. 61 Clozapine is a commonly used antipsychotic because of its lower propensity to induce extrapyramidal adverse effects; however, patients with 22q11.2 deletion syndrome have a high chance of developing clozapine-induced seizures. 22, 23 Therefore, the diagnosis in these cases is directly linked to treatment recommendations. Another example of clinical management based on genetic results was seen in patient 26: at the time of diagnosis of MECP2 duplication (maternally inherited) in the patient, the patient's sister was 6 months pregnant and did not want to know the child's sex. However, after learning that she could also be a carrier of this duplication and, if carrying a boy, there would be a 50% chance of passing on the MECP2 duplication, she agreed to be tested for her carrier status. She was not a carrier of this duplication, and she gave birth to a healthy child. Finally, after genetic diagnosis, patients' families often appreciated being part of support groups, such as the PCDH19 Alliance (http://pcdh19info.org) (patient 25), the Dup 15q Alliance (http://www.dup15q.org (patients 13 and17), and the Rare Disease Foundation.
Limitations
Although our study has several aforementioned strengths, there were also some limitations. Given that our study was a clinical investigation, no gene function analysis was performed. The candidate CNVs and genes identified in our study need to have further functional evaluation and comparison with similar cases. Of note, 16 of the 23 probands underwent further genetic testing through gene panels and whole exome and whole genome sequencing, and no additional pathogenic variants were identified.
Conclusions
This study highlights the importance of reinvestigating adults with childhood-onset epilepsy and ID without a clear etiologic diagnosis. Although most of these patients were thoroughly investigated when their symptoms first appeared, the current genetic technology to allow such diagnosis was not available at that time. In this study, 8 nonrecurrent, rare pathogenic and likely pathogenic CNVs were identified. Two epilepsy syndromes, LGS and JS, were associated with an ABAT duplication and a KIAA2022 deletion, respectively. Further studies and comparison with similar cases are needed to evaluate the functional effects of the CNVs on specific genes. However, interpretation of genetic findings might be complex at times; therefore, phenotyping and continuous collaboration between neurologists and geneticists are important. Alternatively, epilepsy genetics programs in which neurologists seeing adult patients have genetic training could help with etiologic diagnosis and treatment decisions based on genetic findings. 
